国际肿瘤学杂志

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (4): 206-209.doi: 10.3760/cma.j.issn.1673-422X.2018.04.004

• 论著 • 上一篇    下一篇

胸苷酸合成酶表达水平与胃癌术后化疗的相关性研究

刘传超,赵勇   

  1. 237000 安徽医科大学附属六安医院肿瘤外科
  • 出版日期:2018-04-08 发布日期:2018-05-16
  • 通讯作者: 赵勇，Email: 827311206@qq.com E-mail:827311206@qq.com

Study on the correlation between thymidylate synthase expression level and postoperative chemotherapy in gastric cancer

Liu Chuanchao, Zhao Yong.   

  1. Department of Oncology Surgery, Lu′an Hospital, Anhui Medical University, Lu′an 237000, China
  • Online:2018-04-08 Published:2018-05-16
  • Contact: Zhao Yong, Email: 827311206@qq.com E-mail:827311206@qq.com

PDF

700

摘要： 目的 探讨胸苷酸合成酶（TS）的表达水平与胃癌患者临床病理特征及术后氟尿嘧啶类药物化疗预后之间的关系。方法 收集2011年4月至2014年4月在安徽医科大学附属六安医院肿瘤外科行胃癌根治术且术后行辅助化疗的胃癌患者42例，化疗方案为顺铂+卡培他滨或顺铂+替吉奥。采用免疫组织化学法对42例胃癌患者肿瘤组织中TS表达水平进行检测，分析肿瘤组织中TS表达水平与患者临床病理特征及以氟尿嘧啶类药物为基础的化疗患者预后之间的关系。结果 42例胃癌患者中，TS高表达者19例,占45.2%,低表达23例，占54.8%。TS的表达水平与患者年龄、性别、临床分期、分化程度、肿瘤位置、浸润深度、淋巴结转移、脉管癌栓及神经束侵犯均无关（均P＞0.05）。TS低表达和高表达患者的中位无进展生存期分别为35个月、17个月，3年生存率分别为73.9%(17/23)、42.1%(8/19)，差异均有统计学意义（χ2=4.788，P=0.029；χ2=4.369，P=0.037）。在Ⅲ期胃癌患者中，TS低表达患者的中位无进展生存期较TS高表达患者明显延长（33个月∶9个月），差异有统计学意义（χ2=4.731，P=0.030）。结论 TS表达水平与胃癌患者临床病理特征无关，与氟尿嘧啶类药物化疗的预后相关，TS高表达胃癌患者预后较TS低表达患者差。

关键词: 胸苷酸合酶, 胃肿瘤, 化学疗法, 辅助, 氟尿嘧啶

Abstract: Objective To investigate the expression of thymidylate synthase (TS), and the correlations with the clinicopathologcal factors and the prognosis of postoperative fluorouracil chemotherapy in gastric cancer. Methods 42 patients with gastric cancer who underwent radical gastrectomy were collected from April 2011 to April 2014 in Lu′an Hospital of Anhui Medical University, and the chemotherapy regimen was Cisplatin+Capecitabine or Cisplatin+Teggio. The levels of TS in tumor tissues of 42 patients with gastric cancer were detected by immunohistochemical method. The relationships between TS expression level, clinical features and the prognosis of patients treated with fluorouracil chemotherapy were analyzed. Results In 42 patients with gastric cancer, 19 patients (45.2%) have TS high expressions, 23 patients (54.8%) have TS low expressions. There were no significant correlations between the expression of TS and age, sex, clinical stage, differentiation degree, tumor location, depth of invasion, lymph node metastasis, vascular tumor thrombus and nerve bundle invasion (all P＞0.05). There were significant differences between low TS expression and high TS expression in median progression-free survival and 3-year survival rate of patients ［35 months vs. 17 months, 73.9% (17/23) vs. 42.1% (8/19)］, and the differences were statistically significant (χ2=4.788, P=0.029; χ2=4.369, P=0.037). In patients with stage Ⅲ gastric cancer, the median progressionfree survival of patients with low TS expression was significantly prolonged compared to that with high TS expression (33 months vs. 9 months), and the difference was statistically significant (χ2=4.731, P=0.030). Conclusion TS expression levels have no significant correlations with the clinicopathologcal factors, but closely relate to the prognosis of gastric cancer patients treatment with fluorouracil chemotherapy. The chemotherapy prognosis of TS high expression   is worse than that of TS low expression in gastric cancer.

Key words: Thymidylate synthase, Stomach neoplasms, Chemotherapy, adjuvant, Fluorouracil